Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output.

Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Abstract Text:

Output of melatonin or its main metabolite, 6-sulphatoxy melatonin, provides an index of noradrenergic activity in the pineal gland, which is of interest in major depression and during its treatment with antidepressants. Fifteen female depressed outpatients did not differ in levels of 24-hour urinary 6-sulphatoxy melatonin compared with 13 female control subjects. However, a subgroup of the depressed patients (n = 9) who were treated with desipramine showed a significant elevation of 6-sulphatoxy melatonin levels after 1 week of treatment and a return to baseline levels after 6 weeks. There was also a significant negative correlation between 6-sulphatoxy melatonin levels and symptom severity as measured by the Hamilton Rating Scale for Depression after 3 weeks of treatment with desipramine. The other subgroup of depressed patients (n = 6) were treated with adinazolam, a benzodiazepine with antidepressant properties. Despite comparable antidepressant effects to those achieved with desipramine, adinazolam was not associated with any apparent change in 6-sulphatoxy melatonin output during 6 weeks of treatment. There was also no correlation between 6-sulphatoxy melatonin levels and symptom severity.

Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Publishing Authors By Initials

For similar endocrine system: endocrine glands: pineal gland research abstracts see: endocrine system: endocrine glands: pineal gland research

PUBMED ID PMID:

MEDLINE DATE:

Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Psychiatry research

VOLUME: 43

Page Numbers: 177-85

Journal Abbreviation: Psychiatry Res

ISSN: 0165-1781

DAY: 17

MONTH: Aug

YEAR: 1992

Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7911385

Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Keywords Mesh Terms:

KEYWORDS: Pineal Gland

MESH TERMS: physiology

Chemical & Substance for Abstract: Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Information

Substance Name: Melatonin

Registry Number: 73-31-4

Grant and Affiliation Information for Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output.

AFFILIATION: Eating Disorder Program, Toronto Hospital, Ont., Canada.

Country: IRELAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Psychiatry Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output Related Publications

• A radioimmunoassay method for the determination of nedocromil sodium in plasma and urine.
• ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
• Age-related macular degeneration: self-management and reduction of depressive symptoms in a randomized, controlled study.
• Application of item response theory to quantify substance use disorder severity.
• Cell structure and mobilization of lipids and proteins from cotyledon under microgravity influence.
• Chemokine receptors : therapeutic potential in asthma.
• Circadian rhythms. Chronobiology--reducing time.
• Comparative gene expression by WC1+ gammadelta and CD4+ alphabeta T lymphocytes, which respond to Anaplasma marginale, demonstrates higher expression of chemokines and other myeloid cell-associated genes by WC1+ gammadelta T cells.
• Effect of gonadotrophin releasing hormone on conception rate in repeat-breeder dairy cows.
• Engineered iron oxide-adhesion mutants of the Escherichia coli phage lambda receptor.
• Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
• From tip-of-the-tongue (TOT) data to theoretical implications in two steps: when more TOTs means better retrieval.
• Gravisensing: ionic responses, cytoskeleton and amyloplast behavior.
• Identifying housing that poisons: a critical step in eliminating childhood lead poisoning.
• Impaired trace and contextual fear conditioning in aged rats.
• In vivo metabolism of alpha-tocopherol in lipoproteins and liver: studies on rabbits in response to acute cholesterol loading.
• LIPID arrays: new tools in the understanding of membrane dynamics and lipid signaling.
• Loading and boundary condition influences in a poroelastic finite element model of cartilage stresses in a triaxial compression bioreactor.
• Meta-analysis of the effect of exercise interventions on fitness outcomes among adults with type 1 and type 2 diabetes.
• Prenatal diagnostic testing for infantile and late-infantile neuronal ceroid lipofusinoses (NCL) using allele specific primer extension (ASPE).
• Quantitative analysis reveals differential expression of mucin (MUC2) and intestinal trefoil factor mRNAs along the longitudinal axis of rat intestine.
• RHO SIGNALING in vascular diseases.
• Regio- and stereoselective glycosylation: synthesis of 5-haloimidazole alpha-ribonucleosides.
• Solid-state 2H NMR structure of retinal in metarhodopsin I.
• Spermagglutinins in serum and seminal fluid of bulls and their relationship to fertility classification.
• Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha.
• Taste receptors in the gastrointestinal tract. II. L-amino acid sensing by calcium-sensing receptors: implications for GI physiology.
• Transforming growth factor beta receptor family ligands inhibit hepatocyte growth factor synthesis and secretion from astrocytoma cells.
• Treatment of the severe refractory irritable bowel patient.
• Working with a Head Start population with asthma: lessons learned.